Analgesic Effect of Quadratus Lumborum Block in Laparoscopic Hemicolectomy

June 16, 2021 updated by: Evgenii Bespalov,MD, Petrovsky National Research Centre of Surgery
Comparison of the effectiveness: Quadratus lumborum (QL) block by levobupivacaine with placebo.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

All patients will receive standard anaesthesia using fentanyl, protocol, cisatracurium and sevoflurane. Prevention of nausea and vomiting is performing using Apfel score.

All patients will receive post operative multimodal analgesia using paracetamol, ketoprofen, tramadol, and trimeperidine if numerical rating scale > 3 The study assumes use of QL block by levobupivacaine.in comparison with placebo in order to demonstrate the effectiveness of QL block during the operation.

Study Type

Interventional

Enrollment (Anticipated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Moscow, Russian Federation, 119991
        • Recruiting
        • Petrovsky Research National Centre of Surgery ( Petrovsky NRCS)
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients who have undergone left-sided or right-sided laparoscopic hemicolectomy.
  • Patient's willingness and ability to sign an informed consent document

Exclusion Criteria:

  • Allergy to local anesthetics
  • Chronic pain syndrome and associated opioid use.
  • Coagulopathy
  • Uncontrolled diabetes mellitus
  • Physical Status Classification System scale above 3
  • Diseases associated with the pathology of the hypothalamus
  • Diseases associated with the pathology of the pituitary gland
  • Diseases associated with the pathology of the adrenal glands

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Study group
patients receiving general anesthesia with propofol, fentanyl and cisatracurium for induction and sevoflurane, fentanyl and cisatracurium for maintaining anesthesia. Patients receiving postoperative multimodal intravenous analgesia with paracetamol, ketoprofen, tramadol, and trimeperidine. In this group, after induction of anesthesia before the operation, bilateral blockade of the square dorsi muscle is performed under ultrasound guidance using 20 ml of a solution of levobupivacaine 2.5 mg / ml.
QL block will be used for perioperative anesthesia. The blockade will be performed bilaterally by levobupivacaine (20ml) at concentration 0.25%.
Placebo Comparator: Control group
patients receiving general anesthesia with propofol, fentanyl and cisatracurium for induction and sevoflurane, fentanyl and cisatracurium for maintaining anesthesia. Patients receiving postoperative multimodal intravenous analgesia with paracetamol, ketoprofen, tramadol, and trimeperidine. In this group, after induction of anesthesia before surgery, bilateral blockade of the square dorsi muscle is performed under ultrasound guidance using 20 ml of saline.
QL block will be used for perioperative anesthesia. The blockade will be performed bilaterally by levobupivacaine (20ml) at concentration 0.25%.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
NRS (Numeric rating scale)
Time Frame: two hours after surgery
NRS scale 0-10, "no pain"; 10, "worst pain imaginable"
two hours after surgery

Secondary Outcome Measures

Outcome Measure
Time Frame
The need for opioid analgesics during surgery
Time Frame: on operations
on operations
The need for opioid analgesics for postoperative pain relief
Time Frame: 72 hours after surgery
72 hours after surgery
The need for antiemetic drugs to relieve postoperative nausea and vomiting
Time Frame: 12 hours after the surgery
12 hours after the surgery
Occurrence of prolonged post-operative ileus
Time Frame: first two weeks after surgery
first two weeks after surgery
Blood glucose level
Time Frame: after induction into anesthesia, immediately after the end of the surgery, 12 hours after the surgery
after induction into anesthesia, immediately after the end of the surgery, 12 hours after the surgery
The level of blood lactate
Time Frame: after induction into anesthesia, immediately after the end of the surgery, 12 hours after the surgery
after induction into anesthesia, immediately after the end of the surgery, 12 hours after the surgery
The level of cortisol in the blood
Time Frame: after induction into anesthesia and immediately after the end of the surgery
after induction into anesthesia and immediately after the end of the surgery
The level of prolactin in the blood
Time Frame: after induction into anesthesia and immediately after the end of the surgery.
after induction into anesthesia and immediately after the end of the surgery.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 16, 2021

Primary Completion (Anticipated)

April 30, 2022

Study Completion (Anticipated)

May 30, 2022

Study Registration Dates

First Submitted

March 12, 2021

First Submitted That Met QC Criteria

April 13, 2021

First Posted (Actual)

April 19, 2021

Study Record Updates

Last Update Posted (Actual)

June 18, 2021

Last Update Submitted That Met QC Criteria

June 16, 2021

Last Verified

June 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • BEK25011994

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

All patient data will be confidential

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Post Operative Pain

Clinical Trials on Quadratus lumborum block

Subscribe